125 related articles for article (PubMed ID: 35616016)
1. Bacterial infections and antibiotic utilization varies by coronavirus disease 19 (COVID-19) severity in hospitalized cancer patients: Analysis from the first phase of the pandemic.
Maki KR; Steiger SN; Su Y; Boumiza A; Tan CA; Kerpelev M; Seo SK; Cohen N
Infect Control Hosp Epidemiol; 2023 Mar; 44(3):413-419. PubMed ID: 35616016
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
3. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands.
Karami Z; Knoop BT; Dofferhoff ASM; Blaauw MJT; Janssen NA; van Apeldoorn M; Kerckhoffs APM; van de Maat JS; Hoogerwerf JJ; Ten Oever J
Infect Dis (Lond); 2021 Feb; 53(2):102-110. PubMed ID: 33103530
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors for clinically confirmed secondary bacterial infections in patients hospitalized for coronavirus disease 2019 (COVID-19).
Park HS; McCracken CM; Lininger N; Varley CD; Sikka MK; Evans C; Villamagna AH; Makadia JT; McGregor JC
Infect Control Hosp Epidemiol; 2023 Oct; 44(10):1650-1656. PubMed ID: 37184033
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic treatment issues in patients with COVID-19.
Kolář M; Doubravská L; Jakubec P; Sedláková MH; Fišerová K
Vnitr Lek; 2021; 67(8):448-454. PubMed ID: 35459363
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic Use and Associated Risk Factors for Antibiotic Prescribing in COVID-19 Hospitalized Patients.
Martin AJ; Shulder S; Dobrzynski D; Quartuccio K; Pillinger KE
J Pharm Pract; 2023 Apr; 36(2):256-263. PubMed ID: 34291681
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic Prescription in Patients With Coronavirus Disease 2019: Analysis of National Health Insurance System Data in the Republic of Korea.
Choi Y; Kang M; Shin DH; Jung J; Choi SJ; Kim NH; Moon SM; Song KH; Kim ES; Jung J; Kim HB
J Korean Med Sci; 2023 Jun; 38(25):e189. PubMed ID: 37365725
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels.
So W; Simon MS; Choi JJ; Wang TZ; Williams SC; Chua J; Kubin CJ
Intern Emerg Med; 2022 Aug; 17(5):1405-1412. PubMed ID: 35277828
[TBL] [Abstract][Full Text] [Related]
10. Hospital antibiotic consumption-an interrupted time series analysis of the early and late phases of the COVID-19 pandemic in Poland, a retrospective study.
Siewierska M; Gajda M; Opalska A; Brudło M; Krzyściak P; Gryglewska B; Różańska A; Wójkowska-Mach J
Pharmacol Rep; 2023 Jun; 75(3):715-725. PubMed ID: 37017868
[TBL] [Abstract][Full Text] [Related]
11. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
12. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting.
Hughes S; Troise O; Donaldson H; Mughal N; Moore LSP
Clin Microbiol Infect; 2020 Oct; 26(10):1395-1399. PubMed ID: 32603803
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic use during the first 6 months of COVID-19 pandemic in Iran: A large-scale multi-centre study.
Salehi M; Khalili H; Seifi A; Davoudi H; Darazam IA; Jahangard-Rafsanjani Z; Mohammadnejad E; Heydari B; Siahkaly SJM; Tabarsi P; Kalantari S; Menshadi SAD; Babamahmoodi F; Khorvash F; Davarpanah MA; Soltani R; Yaghoobi MH; Anari SAM; Khodadadi J; Aliramezani A; Hantooshzadeh S; Naderi HR; Hajiabdolbaghi M; Elyasi S; Firouzabadi D; Kasgari HA; Roshanzamiri S; Ebrahimpour S
J Clin Pharm Ther; 2022 Dec; 47(12):2140-2151. PubMed ID: 36054303
[TBL] [Abstract][Full Text] [Related]
14. Bacterial co-infections with SARS-CoV-2.
Mirzaei R; Goodarzi P; Asadi M; Soltani A; Aljanabi HAA; Jeda AS; Dashtbin S; Jalalifar S; Mohammadzadeh R; Teimoori A; Tari K; Salari M; Ghiasvand S; Kazemi S; Yousefimashouf R; Keyvani H; Karampoor S
IUBMB Life; 2020 Oct; 72(10):2097-2111. PubMed ID: 32770825
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary bacterial infections in adult patients hospitalized for COVID-19 in standard wards.
Husain M; Valayer S; Poey N; Rondinaud E; d'Humières C; Visseaux B; Lariven S; Lescure FX; Deconinck L
Infect Dis Now; 2022 Jun; 52(4):208-213. PubMed ID: 34896662
[TBL] [Abstract][Full Text] [Related]
16. The interface between COVID-19 and bacterial healthcare-associated infections.
O'Toole RF
Clin Microbiol Infect; 2021 Dec; 27(12):1772-1776. PubMed ID: 34111586
[TBL] [Abstract][Full Text] [Related]
17. A point prevalence survey to assess antibiotic prescribing in patients hospitalized with confirmed and suspected coronavirus disease 2019 (COVID-19).
Tan SH; Ng TM; Tay HL; Yap MY; Heng ST; Loo AYX; Teng CB; Lee TH
J Glob Antimicrob Resist; 2021 Mar; 24():45-47. PubMed ID: 33307276
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic stewardship: Early discontinuation of antibiotics based on procalcitonin level in COVID-19 pneumonia.
Roy A; Powers HR; Craver EC; Nazareno MD; Yarrarapu SNS; Sanghavi DK
J Clin Pharm Ther; 2022 Feb; 47(2):243-247. PubMed ID: 34766357
[TBL] [Abstract][Full Text] [Related]
19. Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial.
Declercq J; Bosteels C; Van Damme K; De Leeuw E; Maes B; Vandecauter A; Vermeersch S; Delporte A; Demeyere B; Vuylsteke M; Lalla M; Smart T; Detalle L; Bouw R; Streffer J; Degeeter T; Vergotte M; Guisez T; Van Braeckel E; Van Der Straeten C; Lambrecht BN
Trials; 2020 Nov; 21(1):934. PubMed ID: 33213529
[TBL] [Abstract][Full Text] [Related]
20. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy.
Chedid M; Waked R; Haddad E; Chetata N; Saliba G; Choucair J
J Infect Public Health; 2021 May; 14(5):570-576. PubMed ID: 33848886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
